Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Cystic Fibrosis Market

ID: MRFR/Pharma/1293-CR
62 Pages
Nidhi Mandole
Last Updated: April 02, 2026

๋‚ญํฌ ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ ์กฐ์‚ฌ ๋ณด๊ณ ์„œ ์น˜๋ฃŒ ๋ฐฉ๋ฒ• ๋ณ„ ์ •๋ณด (์•ฝ๋ฌผ ๋ฐ ์žฅ์น˜), ํˆฌ์—ฌ ๊ฒฝ๋กœ ๋ณ„ (๊ฒฝ๊ตฌ ๋ฐ ํก์ž…), ์•ฝ๋ฌผ ๋“ฑ๊ธ‰ ๋ณ„ (์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ, ์ ์•ก ์šฉํ•ด์ œ, ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ, ํ•ญ์ƒ์ œ ๋ฐ CFTR ์กฐ์ ˆ์ œ) ๋ฐ ์ง€์—ญ๋ณ„ (๋ถ๋ฏธ, ์œ ๋Ÿฝ, ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋ฐ ๊ธฐํƒ€ ์„ธ๊ณ„) - 2032 ๋…„๊นŒ์ง€ ์‹œ์žฅ ์˜ˆ์ธก

๊ณต์œ 
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Cystic Fibrosis Market Infographic
Purchase Options
  1. 1 ์„œ๋ก 
    1. 1.1 ์ •์˜ 8
    2. 1.2 ์—ฐ๊ตฌ ๋ฒ”์œ„ 8
    3. 1.3 ์—ฐ๊ตฌ ๋ชฉํ‘œ 8
    4. 1.4 ๊ฐ€์ • ๋ฐ ํ•œ๊ณ„ 9
      1. 1.4.1 ๊ฐ€์ • 9
      2. 1.4.2 ํ•œ๊ณ„ 9
    5. 1.5 ์‹œ์žฅ ๊ตฌ์กฐ 9
  2. 2 ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก 
    1. 2.1 ์—ฐ๊ตฌ ํ”„๋กœ์„ธ์Šค 10
    2. 2.2 1์ฐจ ์—ฐ๊ตฌ 11
    3. 2.3 2์ฐจ ์—ฐ๊ตฌ 11
  3. 3 ์‹œ์žฅ ์—ญํ•™
    1. 3.1 ๋™์ธ 12
      1. 3.1.1 ์„œ๋ก  12
      2. 3.1.2 ์‹ ์•ฝ ๋ฐ ์น˜๋ฃŒ๋ฒ• ๊ฐœ๋ฐœ 12
      3. 3.1.3 CF ์•ฝ๋ฌผ ์—ฐ๊ตฌ ๋ฐ ๊ฐœ๋ฐœ์— ๋Œ€ํ•œ CFF์˜ ์žฌ์ • ์ง€์›. 12
    2. 3.2 ์ œ์•ฝ 13
      1. 3.2.1 ์„œ๋ก  13
      2. 3.2.2 ์•ฝ๋ฌผ ๋ฐ ์น˜๋ฃŒ์˜ ๋†’์€ ๋น„์šฉ 13
    3. 3.3 ๊ธฐํšŒ 13
    4. 3.4 ๊ณผ์ œ 14
      1. 3.4.1 ๊ฐœ๋ฐœ๋„์ƒ๊ตญ์˜ ํฌ๊ท€ ์งˆํ™˜์— ๋Œ€ํ•œ ์ธ์‹ 14
  4. 4 ์‹œ์žฅ ์š”์ธ ๋ถ„์„
    1. 4.1 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ชจ๋ธ 15
      1. 4.1.1 ๊ณต๊ธ‰์ž์˜ ํ˜‘์ƒ๋ ฅ 15
      2. 4.1.2 ๊ตฌ๋งค์ž์˜ ํ˜‘์ƒ๋ ฅ 15
      3. 4.1.3 ์‹ ๊ทœ ์ง„์ž…์ž์˜ ์œ„ํ˜‘ 16
      4. 4.1.4 ๋Œ€์ฒด์žฌ์˜ ์œ„ํ˜‘ 16
      5. 4.1.5 ๊ฒฝ์Ÿ์˜ ๊ฐ•๋„ 16
  5. 5 ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ
    1. 5.1 ์„œ๋ก  17
    2. 5.2 ์•ฝ๋ฌผ 18
    3. 5.3 ๊ธฐ๊ธฐ 19
    4. 5.4 ๊ธฐํƒ€ ์น˜๋ฃŒ๋ฒ• 20
  6. 6 ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์ง€์—ญ๋ณ„
    1. 6.1 ์„œ๋ก  22
    2. 6.2 ๋ถ๋ฏธ 24
    3. ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„
    4. 6.3 ์œ ๋Ÿฝ 27
    5. ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„
    6. 6.4 ์•„์‹œ์•„ ํƒœํ‰์–‘ 33
    7. ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„
    8. 6.5 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด 38
    9. ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ
    10. ์ง€์—ญ๋ณ„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ
  7. 7 ํšŒ์‚ฌ ์ ์œ ์œจ ๋ถ„์„
  8. 8 ํšŒ์‚ฌ ํ”„๋กœํ•„
    1. 8.1 AbbVie 43
      1. 8.1.1 ํšŒ์‚ฌ ๊ฐœ์š” 43
      2. 8.1.2 ์ œํ’ˆ ๊ฐœ์š” 43
      3. 8.1.3 ์žฌ๋ฌด ์ •๋ณด 44
      4. 8.1.4 ์ฃผ์š” ๊ฐœ๋ฐœ 44.
    2. 8.2 Allergan PLC 46
      1. 8.2.1 ํšŒ์‚ฌ ๊ฐœ์š” 46
      2. 8.2.2 ์ œํ’ˆ ๊ฐœ์š” 46
      3. 8.2.3 ์žฌ๋ฌด ์ •๋ณด 46
      4. 8.2.4 ์ฃผ์š” ๊ฐœ๋ฐœ 46.
    3. 8.3 Chiesi Farmaceutici SpA 48
      1. 8.3.1 ํšŒ์‚ฌ ๊ฐœ์š” 48
      2. 8.3.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š” 48
      3. 8.3.3 ์žฌ๋ฌด ์ •๋ณด 48
      4. 8.3.4 ์ฃผ์š” ๊ฐœ๋ฐœ 49
    4. 8.4 F. Hoffmannโ€“La Roche AG 50
      1. 8.4.1 ํšŒ์‚ฌ ๊ฐœ์š” 50
      2. 8.4.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š” 50
      3. 8.4.3 ์žฌ๋ฌด 50
      4. 8.4.4 ์ฃผ์š” ๊ฐœ๋ฐœ 51
    5. 8.5 Gilead Sciences 52
      1. 8.5.1 ํšŒ์‚ฌ ๊ฐœ์š” 52
      2. 8.5.2 ์ œํ’ˆ ๊ฐœ์š” 52
      3. 8.5.3 ์žฌ๋ฌด 52
      4. 8.5.4 ์ฃผ์š” ๊ฐœ๋ฐœ 52
    6. 8.6 Novartis AG 53
      1. 8.6.1 ํšŒ์‚ฌ ๊ฐœ์š” 53
      2. 8.6.2 ์ œํ’ˆ ๊ฐœ์š” 53
      3. 8.6.3 ์žฌ๋ฌด 53
      4. 8.6.4 ์ฃผ์š” ๊ฐœ๋ฐœ 54
    7. ?
    8. 8.7 Pharmaxis Ltd 55
      1. 8.7.1 ํšŒ์‚ฌ ๊ฐœ์š” 55
      2. 8.7.2 ์ œํ’ˆ ๊ฐœ์š” 55
      3. 8.7.3 ์žฌ๋ฌด 55
      4. 8.7.4 ์ฃผ์š” ๊ฐœ๋ฐœ 56
    9. 8.8 PTC Therapeutics 57
      1. 8.8.1 ํšŒ์‚ฌ ๊ฐœ์š” 57
      2. 8.8.2 ์ œํ’ˆ ๊ฐœ์š” 57
      3. 8.8.3 ์žฌ๋ฌด 57
      4. 8.8.4 ์ฃผ์š” ๊ฐœ๋ฐœ 58
    10. 8.9 Vertex Pharmaceuticals Incorporated 59
      1. 8.9.1 ํšŒ์‚ฌ ๊ฐœ์š” 59
      2. 8.9.2 ์ œํ’ˆ/์‚ฌ์—… ๋ถ€๋ฌธ ๊ฐœ์š” 59
      3. 8.9.3 ์žฌ๋ฌด 59
  9. 9 ํ‘œ ๋ชฉ๋ก
    1. ํ‘œ 1 ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๊ธ€๋กœ๋ฒŒ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 18
    2. ํ‘œ 2 ์ง€์—ญ๋ณ„ ๊ธ€๋กœ๋ฒŒ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์น˜๋ฃŒ์ œ ์‹œ์žฅ, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 19
    3. ํ‘œ 3 ์ง€์—ญ๋ณ„ ๊ธ€๋กœ๋ฒŒ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์˜๋ฃŒ๊ธฐ๊ธฐ ์‹œ์žฅ, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 20
    4. ํ‘œ 4 ์ง€์—ญ๋ณ„ ๊ธ€๋กœ๋ฒŒ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ๊ธฐํƒ€ ์น˜๋ฃŒ์ œ ์‹œ์žฅ, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 21
    5. ํ‘œ 5 ์ง€์—ญ๋ณ„ ๊ธ€๋กœ๋ฒŒ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 23
    6. ํ‘œ 6 ๊ตญ๊ฐ€๋ณ„ ๋ถ๋ฏธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 24
    7. ํ‘œ 7 ๋ถ๋ฏธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 25
    8. ํ‘œ 8 ๋ฏธ๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 26
    9. ํ‘œ 9 ์บ๋‚˜๋‹ค ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 26
    10. ํ‘œ 10 ์œ ๋Ÿฝ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ๊ตญ๊ฐ€๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 28
    11. ํ‘œ 11 ์œ ๋Ÿฝ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 29
    12. ํ‘œ 12 ๋…์ผ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 29
    13. ํ‘œ 13 ํ”„๋ž‘์Šค ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 29
    14. ํ‘œ 14 ์˜๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 30
    15. ํ‘œ 15 ์ดํƒˆ๋ฆฌ์•„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 30
    16. ํ‘œ 16 ์ŠคํŽ˜์ธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 31
    17. ํ‘œ 17 ์„œ์œ ๋Ÿฝ ๋‚˜๋จธ์ง€ ์ง€์—ญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 31
    18. ํ‘œ 18 ๋™์œ ๋Ÿฝ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 32
    19. ํ‘œ 19 ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ๊ตญ๊ฐ€๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 34
    20. ํ‘œ 20 ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 35
    21. ํ‘œ 21 ํ˜ธ์ฃผ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ 2020โ€“2027 ($๋ฐฑ๋งŒ) 35
    22. ํ‘œ 22 ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์ผ๋ณธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, 2020โ€“2027 ($๋ฐฑ๋งŒ) 35
    23. ํ‘œ 23 ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์ค‘๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, 2020โ€“2027 ($๋ฐฑ๋งŒ) 36
    24. ํ‘œ 24 ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์ธ๋„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, 2020โ€“2027 ($๋ฐฑ๋งŒ) 36
    25. ํ‘œ 25 ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๋Œ€ํ•œ๋ฏผ๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, 2020โ€“2027 ($๋ฐฑ๋งŒ) 37
    26. ํ‘œ 26 ๊ธฐํƒ€ ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 37
    27. ํ‘œ 27 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์ง€์—ญ๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 38
    28. ํ‘œ 28 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด ์•„ํ”„๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 39
    29. ํ‘œ 29 ์ค‘๋™ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 40
    30. ํ‘œ 30 ์•„ํ”„๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020-2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 40
    31. ํ‘œ 31 CHIESI FARMACEUTICI SPA: ์ฃผ์š” ๊ฐœ๋ฐœ 49
    32. ํ‘œ 32 VERTEX PHARMACEUTICALS INCORPORATED: ์ฃผ์š” ๊ฐœ๋ฐœ 60
  10. 10 ๊ทธ๋ฆผ ๋ชฉ๋ก
    1. ๊ทธ๋ฆผ 1 MRFR์˜ ์—ฐ๊ตฌ ํ”„๋กœ์„ธ์Šค 10
    2. ๊ทธ๋ฆผ 2 ๊ธ€๋กœ๋ฒŒ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ์— ๋Œ€ํ•œ ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ถ„์„ 15
    3. ๊ทธ๋ฆผ 3 ๊ธ€๋กœ๋ฒŒ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020๋…„ ๋ฐ 2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 17
    4. ๊ทธ๋ฆผ 4 ๊ธ€๋กœ๋ฒŒ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์ง€์—ญ๋ณ„, 2020๋…„(%) 22
    5. ๊ทธ๋ฆผ 5 ๋ถ๋ฏธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ๊ตญ๊ฐ€๋ณ„, 2020๋…„(%) 24
    6. ๊ทธ๋ฆผ 6 ๋ถ๋ฏธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020๋…„ ๋ฐ 2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 25
    7. ๊ทธ๋ฆผ 7 ์œ ๋Ÿฝ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ๊ตญ๊ฐ€๋ณ„, 2020๋…„(%) 27
    8. ๊ทธ๋ฆผ 8 ์œ ๋Ÿฝ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020๋…„ ๋ฐ 2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 28
    9. ๊ทธ๋ฆผ 9 ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ๊ตญ๊ฐ€๋ณ„, 2020๋…„(%) 33
    10. ๊ทธ๋ฆผ 10 ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020๋…„ % 2027๋…„(๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ) 34
    11. ๊ทธ๋ฆผ 11 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์ง€์—ญ๋ณ„, 2020๋…„(%) 38
    12. ๊ทธ๋ฆผ 12 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ, ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„, 2020๋…„ ๋ฐ 2027๋…„ ($๋ฐฑ๋งŒ) 39
    13. ๊ทธ๋ฆผ 13 ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์‹œ์žฅ ์ ์œ ์œจ, 2020๋…„(%) 41
    14. ๊ทธ๋ฆผ 14 ABBVIE: ์ตœ๊ทผ ์žฌ๋ฌด 44
    15. ๊ทธ๋ฆผ 15 ABBVIE: ์‚ฌ์—… ์ˆ˜์ต, 2020๋…„(%) 44
    16. ๊ทธ๋ฆผ 16 ABBVIE: ์ง€๋ฆฌ์  ์ˆ˜์ต, 2020๋…„(%) 45
    17. ๊ทธ๋ฆผ 17 ALLERGAN: ์ตœ๊ทผ ์žฌ๋ฌด 46
    18. ๊ทธ๋ฆผ 18 ALLERGAN: ์‚ฌ์—… ์ˆ˜์ต, 2020๋…„(%) 47
    19. ๊ทธ๋ฆผ 19 ALLERGAN: ์ง€๋ฆฌ์  ์ˆ˜์ต, 2020๋…„(%) 47
    20. ๊ทธ๋ฆผ 20 CHIESI FARMACEUTICI S.P.A.: ์ตœ๊ทผ ์žฌ๋ฌด์ œํ‘œ 48
    21. ๊ทธ๋ฆผ 21 F. HOFFMANN-LA ROCHE AG.: ์ตœ๊ทผ ์žฌ๋ฌด์ œํ‘œ 50
    22. ๊ทธ๋ฆผ 22 F. HOFFMANN-LA ROCHE AG.: ์‚ฌ์—… ์ˆ˜์ต 51
    23. ๊ทธ๋ฆผ 23 GILEAD SCIENCES: ์ตœ๊ทผ ์žฌ๋ฌด์ œํ‘œ 52
    24. ๊ทธ๋ฆผ 24 NOVARTIS AG: ์ตœ๊ทผ ์žฌ๋ฌด์ œํ‘œ 53
    25. ๊ทธ๋ฆผ 25 NOVARTIS AG: ์‚ฌ์—… ์ˆ˜์ต, 2020(%) 54
    26. ๊ทธ๋ฆผ 26 NOVARTIS AG: ์ง€๋ฆฌ์  ์ˆ˜์ต, 2020(%) 54
    27. ๊ทธ๋ฆผ 27 PHARMAXIS LTD: ์ตœ๊ทผ ์žฌ๋ฌด์ œํ‘œ 55
    28. ๊ทธ๋ฆผ 28 PTC THERAPEUTICS: ์ตœ๊ทผ ์žฌ๋ฌด์ œํ‘œ 57
    29. ๊ทธ๋ฆผ 29 PTC THERAPEUTICS: ์ง€๋ฆฌ์  ์ˆ˜์ต(%) 58
    30. ๊ทธ๋ฆผ 30 PTC THERAPEUTICS: R&D ๋น„์šฉ, 2020(%) 58
    31. ๊ทธ๋ฆผ 31 VERTEX PHARMACEUTICALS INCORPORATED: ์ตœ๊ทผ ์žฌ๋ฌด์ œํ‘œ 59
    32. ๊ทธ๋ฆผ 32 VERTEX PHARMACEUTICALS INCORPORATED: ์‚ฌ์—… ์ˆ˜์ต 60
    33. ๊ทธ๋ฆผ 33 VERTEX PHARMACEUTICALS INCORPORATED: ์ง€๋ฆฌ์  ์ˆ˜์ต 60

ย 

์‹œ์žฅ ์„ธ๋ถ„ํ™” ํƒญ

๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์น˜๋ฃŒ ๋ฐฉ๋ฒ• ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)

  • ์˜์•ฝํ’ˆ
  • ๊ธฐ๊ธฐ

๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ํˆฌ์—ฌ ๊ฒฝ๋กœ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)

  • ๊ฒฝ๊ตฌ์šฉ
  • ํก์ž…์šฉ

๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์•ฝ๋ฌผ ๊ณ„์—ด ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)

  • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
  • ์ ์•ก์šฉํ•ด์ œ
  • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
  • ํ•ญ์ƒ์ œ
  • CFTR ์กฐ์ ˆ์ œ

๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์ง€์—ญ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)

  • ๋ถ๋ฏธ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)
    • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๋ถ๋ฏธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ์•ฝ๋ฌผ
      • ๊ธฐ๊ธฐ
    • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ๋ถ๋ฏธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ๊ฒฝ๊ตฌ
      • ํก์ž…
    • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ๋ถ๋ฏธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
      • ์ ์•ก์šฉํ•ด์ œ
      • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
      • ํ•ญ์ƒ์ œ
      • CFTR ์กฐ์ ˆ์ œ
    • ๋ฏธ๊ตญ ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)
    • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๋ฏธ๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ์•ฝ๋ฌผ
      • ๊ธฐ๊ธฐ
    • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ๋ฏธ๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ๊ฒฝ๊ตฌ
      • ํก์ž…
    • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ๋ฏธ๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
      • ์ ์•ก์šฉํ•ด์ œ
      • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
      • ํ•ญ์ƒ์ œ
      • CFTR ์กฐ์ ˆ์ œ
    • ์บ๋‚˜๋‹ค ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
    • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์บ๋‚˜๋‹ค ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ์•ฝ๋ฌผ
      • ๊ธฐ๊ธฐ
    • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์บ๋‚˜๋‹ค ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ๊ฒฝ๊ตฌ
      • ํก์ž…
    • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์บ๋‚˜๋‹ค ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
      • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
      • ์ ์•ก์šฉํ•ด์ œ
      • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
      • ํ•ญ์ƒ์ œ
      • CFTR ์กฐ์ ˆ์ œ
    • ์œ ๋Ÿฝ ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)
      • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์œ ๋Ÿฝ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์•ฝ๋ฌผ
        • ๊ธฐ๊ธฐ
      • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์œ ๋Ÿฝ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ๊ฒฝ๊ตฌ
        • ํก์ž…
      • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์œ ๋Ÿฝ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
        • ์ ์•ก์šฉํ•ด์ œ
        • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
        • ํ•ญ์ƒ์ œ
        • CFTR ์กฐ์ ˆ์ œ
      • ๋…์ผ ์ „๋ง (2018-2030๋…„ 10์–ต ๋‹ฌ๋Ÿฌ)
      • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๋…์ผ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์•ฝ๋ฌผ
        • ๊ธฐ๊ธฐ
      • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ๋…์ผ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ๊ฒฝ๊ตฌ
        • ํก์ž…
      • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ๋…์ผ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
        • ์ ์•ก ์šฉํ•ด์ œ
        • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
        • ํ•ญ์ƒ์ œ
        • CFTR ์กฐ์ ˆ์ œ
      • ํ”„๋ž‘์Šค ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
      • ํ”„๋ž‘์Šค ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ํ˜„ํ™ฉ
        • ์•ฝ๋ฌผ
        • ๊ธฐ๊ธฐ
      • ํ”„๋ž‘์Šค ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ํ˜„ํ™ฉ
        • ๊ฒฝ๊ตฌ
        • ํก์ž…
      • ํ”„๋ž‘์Šค ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ํ˜„ํ™ฉ
        • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
        • ์ ์•ก์šฉํ•ด์ œ
        • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
        • ํ•ญ์ƒ์ œ
        • CFTR ์กฐ์ ˆ์ œ
      • ์˜๊ตญ ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)
      • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์˜๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์•ฝ๋ฌผ
        • ๊ธฐ๊ธฐ
      • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์˜๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ๊ฒฝ๊ตฌ
        • ํก์ž…
      • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์˜๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
        • ์ ์•ก์šฉํ•ด์ œ
        • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
        • ํ•ญ์ƒ์ œ
        • CFTR ์กฐ์ ˆ์ œ
      • ์ดํƒˆ๋ฆฌ์•„ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
      • ์ดํƒˆ๋ฆฌ์•„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ํ˜„ํ™ฉ
        • ์•ฝ๋ฌผ
        • ๊ธฐ๊ธฐ
      • ์ดํƒˆ๋ฆฌ์•„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ํ˜„ํ™ฉ
        • ๊ฒฝ๊ตฌ
        • ํก์ž…
      • ์ดํƒˆ๋ฆฌ์•„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ํ˜„ํ™ฉ
        • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
        • ์ ์•ก์šฉํ•ด์ œ
        • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
        • ํ•ญ์ƒ์ œ
        • CFTR ์กฐ์ ˆ์ œ
      • ์ŠคํŽ˜์ธ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
      • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์ŠคํŽ˜์ธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์•ฝ๋ฌผ
        • ๊ธฐ๊ธฐ
      • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์ŠคํŽ˜์ธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ๊ฒฝ๊ตฌ
        • ํก์ž…
      • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์ŠคํŽ˜์ธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
        • ์ ์•ก์šฉํ•ด์ œ
        • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
        • ํ•ญ์ƒ์ œ
        • CFTR ์กฐ์ ˆ์ œ
      • ์œ ๋Ÿฝ ๊ธฐํƒ€ ์ง€์—ญ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
      • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์œ ๋Ÿฝ ๊ธฐํƒ€ ์ง€์—ญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์•ฝ๋ฌผ
        • ๊ธฐ๊ธฐ
      • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์œ ๋Ÿฝ ๊ธฐํƒ€ ์ง€์—ญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ๊ฒฝ๊ตฌ
        • ํก์ž…
      • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์œ ๋Ÿฝ ๊ธฐํƒ€ ์ง€์—ญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
        • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
        • ์ ์•ก์šฉํ•ด์ œ
        • ๊ธฐ๊ด€์ง€ํ™•์žฅ์ œ
        • ํ•ญ์ƒ์ œ
        • CFTR ์กฐ์ ˆ์ œ
      • ์•„์‹œ์•„ ํƒœํ‰์–‘ ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030๋…„)
        • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ์•ฝ๋ฌผ
          • ๊ธฐ๊ธฐ
        • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ๊ฒฝ๊ตฌ
          • ํก์ž…
        • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
          • ์ ์•ก์šฉํ•ด์ œ
          • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
          • ํ•ญ์ƒ์ œ
          • CFTR ์กฐ์ ˆ์ œ
        • ์ค‘๊ตญ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
        • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์ค‘๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ์˜์•ฝํ’ˆ
          • ๊ธฐ๊ธฐ
        • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์ค‘๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ๊ฒฝ๊ตฌ
          • ํก์ž…
        • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์ค‘๊ตญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
          • ์ ์•ก์šฉํ•ด์ œ
          • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
          • ํ•ญ์ƒ์ œ
          • CFTR ์กฐ์ ˆ์ œ
        • ์ผ๋ณธ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
        • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์ผ๋ณธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ์•ฝ๋ฌผ
          • ๊ธฐ๊ธฐ
        • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์ผ๋ณธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ๊ฒฝ๊ตฌ
          • ํก์ž…
        • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์ผ๋ณธ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
          • ์ ์•ก์šฉํ•ด์ œ
          • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
          • ํ•ญ์ƒ์ œ
          • CFTR ์กฐ์ ˆ์ œ
        • ์ธ๋„ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
        • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์ธ๋„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ์•ฝ๋ฌผ
          • ๊ธฐ๊ธฐ
        • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์ธ๋„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ๊ฒฝ๊ตฌ
          • ํก์ž…
        • ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ์ธ๋„ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
          • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
          • ์ ์•ก์šฉํ•ด์ œ
          • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
          • ํ•ญ์ƒ์ œ
          • CFTR ์กฐ์ ˆ์ œ
        • ํ˜ธ์ฃผ ์ „๋ง (10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
        • ํ˜ธ์ฃผ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ํ˜„ํ™ฉ
          • ์•ฝ๋ฌผ
          • ๊ธฐ๊ธฐ
        • ํ˜ธ์ฃผ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ํ˜„ํ™ฉ
          • ๊ฒฝ๊ตฌ
          • ํก์ž…
        • ํ˜ธ์ฃผ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์•ฝ๋ฌผ ๊ณ„์—ด๋ณ„ ํ˜„ํ™ฉ
          • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
          • ์ ์•ก์šฉํ•ด์ œ
          • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
          • ํ•ญ์ƒ์ œ
          • CFTR ์กฐ์ ˆ์ œ
        • ์•„์‹œ์•„ ํƒœํ‰์–‘ ์ง€์—ญ ๊ธฐํƒ€ ์ง€์—ญ ์ „๋ง (2018-2030๋…„, 10์–ต ๋‹ฌ๋Ÿฌ)
        • ์•„์‹œ์•„ ํƒœํ‰์–‘ ์ง€์—ญ ๊ธฐํƒ€ ์ง€์—ญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์น˜๋ฃŒ ๋ฐฉ๋ฒ•
          • ์•ฝ๋ฌผ
          • ๊ธฐ๊ธฐ
        • ์•„์‹œ์•„ ํƒœํ‰์–‘ ์ง€์—ญ ๊ธฐํƒ€ ์ง€์—ญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ํˆฌ์—ฌ ๊ฒฝ๋กœ
          • ๊ฒฝ๊ตฌ
          • ํก์ž…
        • ์•„์‹œ์•„ ํƒœํ‰์–‘ ์ง€์—ญ ๊ธฐํƒ€ ์ง€์—ญ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์•ฝ๋ฌผ ํด๋ž˜์Šค
          • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
          • ์ ์•ก ์šฉํ•ด์ œ
          • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
          • ํ•ญ์ƒ์ œ
          • CFTR ์กฐ์ ˆ์ œ
        • ๊ธฐํƒ€ ๊ตญ๊ฐ€ ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
          • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๊ธฐํƒ€ ๊ตญ๊ฐ€ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
            • ์•ฝ๋ฌผ
            • ๊ธฐ๊ธฐ
          • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ๊ธฐํƒ€ ๊ตญ๊ฐ€ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
            • ๊ฒฝ๊ตฌ
            • ํก์ž…
          • ์•ฝ๋ฌผ๋ณ„ ๊ธฐํƒ€ ๊ตญ๊ฐ€ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ํด๋ž˜์Šค
            • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
            • ์ ์•ก ์šฉํ•ด์ œ
            • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
            • ํ•ญ์ƒ์ œ
            • CFTR ์กฐ์ ˆ์ œ
          • ์ค‘๋™ ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
          • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์ค‘๋™ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
            • ์•ฝ๋ฌผ
            • ๊ธฐ๊ธฐ
          • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์ค‘๋™ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
            • ๊ฒฝ๊ตฌ
            • ํก์ž…
          • ์•ฝ๋ฌผ๋ณ„ ์ค‘๋™ ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ํด๋ž˜์Šค
            • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
            • ์ ์•ก ์šฉํ•ด์ œ
            • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
            • ํ•ญ์ƒ์ œ
            • CFTR ์กฐ์ ˆ์ œ
          • ์•„ํ”„๋ฆฌ์นด ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
          • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ์•„ํ”„๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
            • ์•ฝ๋ฌผ
            • ๊ธฐ๊ธฐ
          • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ์•„ํ”„๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
            • ๊ฒฝ๊ตฌ
            • ํก์ž…
          • ์•ฝ๋ฌผ๋ณ„ ์•„ํ”„๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ํด๋ž˜์Šค
            • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
            • ์ ์•ก ์šฉํ•ด์ œ
            • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
            • ํ•ญ์ƒ์ œ
            • CFTR ์กฐ์ ˆ์ œ
          • ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด ์ „๋ง(10์–ต ๋‹ฌ๋Ÿฌ, 2018-2030)
          • ์น˜๋ฃŒ ๋ฐฉ๋ฒ•๋ณ„ ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
            • ์•ฝ๋ฌผ
            • ๊ธฐ๊ธฐ
          • ํˆฌ์—ฌ ๊ฒฝ๋กœ๋ณ„ ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ
            • ๊ฒฝ๊ตฌ
            • ํก์ž…
          • ์•ฝ๋ฌผ๋ณ„ ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด ๋‚ญํฌ์„ฑ ์„ฌ์œ ์ฆ ์ˆ˜์—…
            • ์ทŒ์žฅ ํšจ์†Œ ๋ณด์ถฉ์ œ
            • ์ ์•ก ์šฉํ•ด
            • ๊ธฐ๊ด€์ง€ ํ™•์žฅ์ œ
            • ํ•ญ์ƒ์ œ
            • CFTR ๋ณ€์กฐ๊ธฐ
Case Study Cover Image
์‚ฌ๋ก€ ์—ฐ๊ตฌ

Aerospace & Defense

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization โœ“ โœ“ โœ“
Direct Access to Analyst โœ“ โœ“ โœ“
Deliverable Format โœ“ โœ“ โœ“
Platform Access โœ— โœ— โœ“
Discount on Next Purchase 10% 15% 15%
Printable Versions โœ— โœ— โœ“